Clinical Utility of PCA3 Assay in Patients with Suspicious Prostate Cancer
N A, A., AM, S., EA, E., N R, M., MA, A., AD, A. (2017). Clinical Utility of PCA3 Assay in Patients with Suspicious Prostate Cancer. EKB Journal Management System, 66(1), 234-236. doi: 10.12816/0034658
AbdelSattar N A; Seif AM; ELHadidi EA; Mohamed N R; Abu El Naga MA; Abdelhakam AD. "Clinical Utility of PCA3 Assay in Patients with Suspicious Prostate Cancer". EKB Journal Management System, 66, 1, 2017, 234-236. doi: 10.12816/0034658
N A, A., AM, S., EA, E., N R, M., MA, A., AD, A. (2017). 'Clinical Utility of PCA3 Assay in Patients with Suspicious Prostate Cancer', EKB Journal Management System, 66(1), pp. 234-236. doi: 10.12816/0034658
N A, A., AM, S., EA, E., N R, M., MA, A., AD, A. Clinical Utility of PCA3 Assay in Patients with Suspicious Prostate Cancer. EKB Journal Management System, 2017; 66(1): 234-236. doi: 10.12816/0034658

Clinical Utility of PCA3 Assay in Patients with Suspicious Prostate Cancer

The Egyptian Journal of Hospital Medicine
Article 31, Volume 66, Issue 1, January 2017, Page 234-236  XML PDF (231.12 K)
Document Type: Original Article
DOI: 10.12816/0034658
View on SCiNiTO View on SCiNiTO
Authors
AbdelSattar N A1; Seif AM1; ELHadidi EA1; Mohamed N R2; Abu El Naga MA1; Abdelhakam AD1
1Department of Clinical and Chemical Pathology, Faculty of Medicine, Ainshams University.
2Department of Clinical and Chemical Pathology, Faculty of Medicine, Ainshams University
Abstract
  Background: this study evaluated the clinical utility of the PCA3 assay in guiding initial biopsy decisions in prostate cancer. Subjects and Methods: this study was conducted on fifty patients selected from the Urology Department at Ain Shams University Hospitals and scheduled for prostate biopsy after digital rectal examination first catch urine was collected. PCA3 scores were determined using RT-PCR and compared to biopsy outcome. The diagnostic accuracy of PCA3 was compared to total prostate specific antigen and %free prostate specific antigen.Results: the best cutoff for PCA3 was 4.6 folds (RQ). This cutoff had a diagnostic sensitivity of 94.7%, specificity 95% and area under the curve (AUC) was 0.978. Total PSA at the cutoff 10 ng/mL had a diagnostic sensitivity 68%, specificity 70% and AUC was 0.766. At cut off 19%, f/t PSA ratio had a diagnostic sensitivity 38%, diagnostic specificity 90 %, and AUC was 0.529.
Conclusions: the PCA3 assay can aid in guiding biopsy decisions. It is superior to total prostate specific antigen and %free prostate specific antigen in predicting initial biopsy outcome, and may be indicative of prostate cancer aggressiveness.
 
Keywords
Prostate Cancer; PCA3; PSA; BPH
Statistics
Article View: 94
PDF Download: 240